Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition by Hackl, Christina et al.
RESEARCH ARTICLE Open Access
Activating transcription factor-3 (ATF3) functions
as a tumor suppressor in colon cancer and is
up-regulated upon heat-shock protein 90 (Hsp90)
inhibition
Christina Hackl1, Sven A Lang1, Christian Moser1, Akira Mori1, Stefan Fichtner-Feigl1, Claus Hellerbrand2,
Wolfgang Dietmeier3, Hans J Schlitt1, Edward K Geissler1, Oliver Stoeltzing1,4*
Abstract
Background: Activating transcription factor-3 (ATF3) is involved in the complex process of cellular stress response.
However, its exact role in cancer is discussed controversially because both tumor suppressive and oncogenic
effects have been described. Here we followed-up on our previous observation that inhibition of Hsp90 may
increase ATF3 expression and sought to determine the role of ATF3 in colon cancer.
Methods: Regulation of ATF3 was determined in cancer cells using signaling inhibitors and a heat-shock protein-
90 (Hsp90) antagonist. Human HCT116 cancer cells were stably transfected with an ATF3-shRNA or a luciferase-
shRNA expression plasmid and alterations in cell motility were assessed in migration assays. The impact of ATF3
down-regulation on cancer growth and metastasis were investigated in a subcutaneous tumor model, a model of
hepatic tumor growth and in a model of peritoneal carcinomatosis. Human colon cancer tissues were analyzed for
ATF3 expression.
Results: The results show that therapeutic Hsp90 inhibition substantially up-regulates the expression of ATF3 in
various cancer cells, including colon, gastric and pancreatic cancer. This effect was evident both in vitro and in vivo.
RNAi mediated knock-down of ATF3 in HCT116 colon cancer cells significantly increased cancer cell migration in
vitro. Moreover, in xenogenic mouse models, ATF3 knock-down promoted subcutaneous tumor growth and
hepatic metastasis, as well as peritoneal carcinomatosis. Importantly, ATF3 expression was lower in human colon
cancer specimens, as compared to corresponding normal surrounding tissues, suggesting that ATF3 may represent
a down-regulated tumor suppressor in colon cancer.
Conclusion: In conclusion, ATF3 down-regulation in colon cancer promotes tumor growth and metastasis.
Considering that blocking Hsp90 induces ATF3 expression, Hsp90 inhibition may represent a valid strategy to treat
metastatic colon cancer by up-regulating this anti-metastatic transcription factor.
Background
Heat shock protein 90 (Hsp90) targeting has emerged as
a valuable strategy for cancer therapy [1,2], because
these proteins are being up-regulated in malignant and
non-malignant cells types upon exposure to a variety of
stressors [3]. At constitutive levels, heat-shock proteins
regulate proper folding and stabilization of abundant
intracellular proteins, and their stress-associated induc-
tion improves cell survival. Hsp90, one of the most stu-
died molecular chaperons, is overexpressed in tumor
cells and is essential for the stability and function of a
wide range of oncogenic client proteins [4]. These
Hsp90 clients comprise kinases such as ERBB2, EGFR,
CDK4, RAF, AKT, cMET and BCR-ABL, and transcrip-
tion factors such as HIF-1a, STAT3, and STAT5 [2,5,6].
Thus, Hsp90 is a promising target for cancer therapy, as
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demonstrated by the expanding armamentarium of
Hsp90 inhibitors and by new clinical studies incorporat-
ing the use of these inhibitors [7]. Nevertheless, due to
the broad and complex inhibition of multiple signaling
pathways affected by Hsp90, the biological effects
remain poorly defined and incompletely understood.
We recently demonstrated that therapeutic inhibition
of Hsp90 not only elicits antineoplastic efficacy through
blocking oncogenic signaling, but also up-regulates cer-
tain signaling molecules in human colon carcinoma cell
lines. One of these molecules is activating transcription
factor-3 (ATF3), which is Hsp90-inhibitor inducible in
HCT116, SW620 and HT29 colon cancer cells [8].
Importantly, such protein up-regulation in response to
Hsp90 inhibition has thus far only been reported for
certain other heat-shock proteins such as HSF1 and
Hsp70. This response may counteract the anti-neoplastic
potential of Hsp90 inhibitors for the following reasons
[9,10]. ATF3 belongs to the ATF/cyclic AMP response
element binding (CREB) family of transcription factors
and most cells have very weak or absent ATF3 expres-
sion under steady-state conditions. A significant increase
in ATF3 can be observed when cell-stress is induced
[11], making ATF3 an universal „adaptive response
gene” [12,13].
Importantly, different roles for ATF3 have been pro-
posed. In normal tissues, ATF3 may promote both
apoptosis and cell proliferation [13], while in neoplasms
it has been identified as either an oncogene or as tumor
suppressor, depending on tumor entity and grade
[13-15]. For instance, ATF3 can mediate pro-apoptotic
effects in human mammary epithelial cells, whereas in
breast cancer cells (MCF10A) it may promote cell survi-
val, motility and invasiveness [15]. Transgenic mice that
overexpress ATF3 in basal epithelial cells develop epi-
dermal hyperplasia, dysplastic lesions and oral squamous
cell carcinoma [16]. Also in favor of oncogenicity, the
tumor suppressor gene Drg-1 mediates its anti-meta-
static properties through ATF3 down-regulation in pros-
tate cancer [17].
In colon cancer, the effects of ATF3 expression are
particularly perplexing. In one respect, ATF3 was shown
to be overexpressed in human colon cancer specimens
and appears to promote tumor growth and migration in
an experimental HT29 colon cancer model [18,19]. In
another respect, ATF3 has been described to mediate
anti-neoplastic and anti-invasive effects of non-steroidal
anti-inflammatory drugs (i.e. COX-2 inhibitors) in color-
ectal cancer [14]. In the present study, we sought to
clarify ATF3 regulation and its role in human colon
cancer using xenogenic mouse models. We hypothesized
that Hsp90 inhibitor-mediated induction of ATF3
expression does not counteract the anti-neoplastic and
anti-metastatic potential of Hsp90 targeting agents.
Methods
Cell culture
The human colorectal cancer cell lines HCT116, SW620
and HT29 were obtained from the American Type Cul-
ture Collection (Manassas, VA). The human gastric can-
cer cell line TMK-1 was obtained from Eiichi Tahara
(University of Hiroshima, Hiroshima, Japan). The meta-
static human pancreatic cancer cell line L3.6pl was kindly
provided by Dr. I.J. Fidler (The University of Texas, MD
Anderson Cancer Center, Houston, TX). HCT116 and
SW620 cells were cultured in RPMI 1640, whereas TMK-
1, HT29 and L3.6pl were grown in DMEM supplemented
with 20% FCS (HCT116 and SW620), 15% FCS (L3.6pl),
or 10% FCS (HT29, TMK-1). All in vitro experiments
were performed at 60 - 70% cell density to reduce effects
of confluence. Cell growth rates of transfected cells were
assessed by MTT assays, as previously described [20].
Stable transfection
HCT116 cells were stable transfected with either an
ATF3-shRNA (TIB Molbiol; Berlin, Germany) or a luci-
ferase-shRNA (Luc-shRNA) expression plasmid (TIB
Molbiol; Berlin, Germany) by using the Lipofectamine
transfection reagent (Invitrogen; Karlsruhe, Germany).
Cells were grown and expanded in selective medium
containing neomycin (G418, Sigma Aldrich, Deisenho-
fen, Germany). Successful transfection was verified by
Western blotting and semi-quantitative PCR for ATF3.
Reagents and antibodies
The water-soluble Hsp90 inhibitor 17-(dimethylami-
noethylamino)-17-demethoxy-geldanamycin (17-DMAG)
was purchased from Invivogen (Cayla-Invivogen) and
was applied as previously published [8]. Antibodies
against ATF3 and anti-b-actin were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA). b-actin served as
a loading control in Western blotting.
Western blot analysis
Protein was extracted from whole-cell lysates with RIPA
buffer as described before and 50-μg protein samples were
subjected to Western blotting on a denaturing 10% sodium
dodecyl sulfate-polyacrylamide gel [20]. Membranes were
probed for ATF3 and b-actin. For induction of ATF3 in
vitro, the Hsp90 inhibitor 17-DMAG (100 ng/ml) was
added to cell cultures for indicated times and ATF3 pro-
tein analysis was performed thereafter. Expression of
ATF3 in 17-DMAG treated tumors was similarly deter-
mined by lysis of snap frozen tumor tissues and subse-
quent Western blotting, as described [20].
Real-time PCR
Real-time PCR was performed as we have previously
described [21]. Primer pairs were as follows: ATF3
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forward 5-’ctgcagaaagagtcggag-3’ and reverse 5’-
tgagcccggacaatacac-3’; VEGF-A forward 5’-gcacccatggca-
gaaggaggag-3’ and reverse 5’-agcccccgcatcgcatcag-3’;
HIF-1a forward taccatgccccagattcaggat and reverse
tcagtggtggcagtggtagtgg; GLUT-1 forward 5’-aactcttcagc-
cagggtccac-3’ and reverse 5’-cacagtgaagatgatgaagac-3’.
Real-time PCR was done using the LightCycler system
and Roche fast-Start Light Cycler-Master Hybridization
Probes master mix (Roche Diagnostics) [20].
Migration Assays
Migration assays were performed using modified Boyden
chambers, as described elsewhere [21]. Briefly, 105 cells
were resuspended in 1% FCS medium and seeded into
8-μm filter pores inserts (Becton Dickinson Bioscience).
10% FCS-enriched medium ± 17-DMAG (100 nM)
served as chemoattractant. After incubation, migrated
cells were stained (Diff-Quick reagent, Dade Behring)
and counted in four random fields.
Animal models
Eight-week-old male nude mice (Charles River, Sulzfeld,
Germany) were used. Experiments were approved by the
Institutional Animal Care and Use Committee of the
University of Regensburg and the regional authorities
(Regierung der Oberpfalz, reference number HIF1_2004)
and in accordance to the “Guidelines for the Welfare of
Animals in Experimental Neoplasia” published by The
United Kingdom Coordinating Committee on Cancer
Research. In experiments, animals were weighed daily
and monitored for weight-loss and other signs of
distress.
Tumour models
(1) One-million human cancer cells (TMK-1, L3.6pl)
were implanted into the subcutis of nude mice, as
described [8]. After implantation, tumors were allowed
to grow to a volume of 400 mm3 until treatment with
either the Hsp90 inhibitor 17-DMAG (3 × 25 mg/kg/
week; i.p.), or PBS (control) was started. This dose has
proven antineoplastic potential in previous models
[8,20]. Tumors were harvested after 14 days of treat-
ment to determine ATF3 protein expression (n = 3 per
group).
(2) One-million ATF3-shRNA, or Luc-shRNA trans-
fected HCT116 human colorectal cancer cells were
injected into the subcutis of nude mice (n = 9-10 per
group). Tumor diameters were measured every other
day, and volumes calculated using the estimation: width2
× length × 0.5.
(3) One-million ATF3-shRNA or Luc-shRNA trans-
fected HCT116 cells were injected into the right lower
liver lobe of mice to determine hepatic growth, as pre-
viously described [22]. Animals were monitored daily
and sacrificed on day 28 (n = 9-10/group). Following
necropsy, liver weight was measured and all tumor
nodules counted and weighed.
(4) For testing peritoneal carcinomatosis, stable trans-
fected HCT116 cells (3 × 106) were implanted into the
abdominal cavity by intraperitoneal injection, as pre-
viously described [23]. Mice were monitored for 28 days
and sacrificed; animals were evaluated for the presence
of ascites and tumor nodules were counted.
Immunohistochemical analysis
Cryosections (7 μm) and paraffin-embedded sections
(5 μm) were cut from xenograft tumors for immunohis-
tochemical analyses. CD31-positive vessel area was ana-
lyzed by converting images to grey scale and setting a
consistent threshold for all slides, as described [20,24].
Vessel area is expressed as pixels per high-power
field [20].
Human tissues
For the analysis of ATF3 mRNA expression, snap frozen
tissue samples of primary human colon carcinomas
(n = 5) and corresponding non-neoplastic colon tissues
(n = 5) were obtained from the anonymized tumor tis-
sue bank of the Department of Pathology (University of
Regensburg), as approved by clinical ethics committee
[25]. Tumor characteristics were as follows: #1 sigmoid
colon: pT3, L0, V0, pN0, R0; #2 cecum: pT4, pN2
(5/12), M1 (per), G2, R1, L1, V1; #3 sigmoid colon: pT3,
pN0 (0/15), G2, R0, L0, V0; #4 cecum: pT3, pN2 (4/24),
G3, L1, V0, R0; #5 sigmoid colon: pT3, pN2, G2, R0, L1,
V0. Patients did not receive neoadjuvant therapy or che-
motherapy before surgery.
Statistical Analyses
Results from in vivo experiments were analyzed for sig-
nificant outliers using Grubb’s test http://www.graph-
pad.com. Tumor-associated variables in in vivo
experiments were tested for statistical significance using
the Mann-Whitney U test for non-parametric data. The
two-sided Student t test was applied for analysis of in
vitro data. All results are expressed as the mean ± SEM.
Results
Regulation and expression of ATF3 in cancer cells
We previously observed that treatment of HCT116 and
SW620 colon cancer cells with an Hsp90 inhibitor (17-
DMAG) substantially up-regulates constitutive ATF3
expression [8]. The biological effects of Hsp90 inhibitor-
mediated induction of ATF3 are currently not known.
To further validate these results, we investigated
whether blocking Hsp90 also leads to ATF3 up-regula-
tion in other human cancer cell types. Indeed we found
that blocking Hsp90 induces ATF3 protein expression
in human gastric (TMK-1), colon (HT29, HCT116,
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SW620), and pancreatic (L3.6pl) cancer cell lines (Figure
1A and [8]). These results were validated in vivo using a
model of subcutaneously implanted gastric (TMK-1), or
pancreatic (L3.6pl) cancer cells where Hsp90 inhibitor
treatment markedly induced ATF3 expression in respec-
tive tumors (Figure 1B).
Since blocking Hsp90 interferes with multiple cell sig-
naling pathways, including MAPK/Erk, PI-3K/Akt, p38
and SAPK, we used in HCT116 cell line selective signal-
ing inhibitors to determine the predominant signaling
pathway involved in this Hsp90-inhibitor mediated
ATF3 up-regulation (Figure 2). Inhibition of SAPK
(SP600125) most robustly up-regulated ATF3 mRNA
expression (Figure 2A). However, we additionally
observed on a protein level that inhibition of either
MAPK/Erk (UO126), or p38 (SB203580), could also
up-regulate ATF3 expression in colon cancer cells
(Figure 2B). We conclude from these experiments that
ATF3 expression in colon cancer cells is complexly con-
trolled through the interaction of multiple molecular
signaling pathways. Because Hsp90 inhibition is known
to affect a broad variety of signaling pathways, it is rea-
sonable to conclude that inhibitors such as 17-DMAG
overall lead to a net-gain in ATF3 expression.
Effects of down-regulating ATF3 in colon cancer cells
In view of the fact that ATF3 is stress-inducible and
continuously detectable in colon cancer cells, we used
an shRNA approach for specifically targeting ATF3
in HCT116 colon cancer cells, with the intention to
determine the biological effects of a further ATF3
down-regulation in this cancer entity. Successful stable
transfection with an ATF3-shRNA plasmid was verified
by Western blotting and real-time PCR (Figure 3A, B).
Importantly, down-regulation of ATF3 markedly
increased the migration ability of colon cancer cells in
vitro (Figure 3C). Together, these in vitro experiments
indicate that ATF3 down-regulation harbors the poten-
tial to increase the metastatic potential of colon cancer
cells.
Impact of ATF3 down-regulation on tumor growth in vivo
The effects of diminished ATF3 expression on tumor
growth in vivo were first investigated in a subcutaneous
tumor model using HCT116 cells. The results show that
down-regulation of ATF3 by ATF3-shRNA leads
to an increased tumor growth rate, as compared to
Luc-shRNA transfected control cells (Figure 4A, B).
Importantly, in vitro growth rates of Luc-shRNA and
ATF3-shRNA transfected HCT116 cells were statistically
Figure 1 Induction of ATF3 by Hsp90 inhibition in colon cancer
in vitro and in vivo. Western blot analysis was performed to
determine alterations in ATF3 expression upon inhibition of Hsp90
with 17-DMAG. A) Treatment of human gastric (TMK-1), colon
(HT29), or pancreatic (L3.6pl) cancer cells with 17-DMAG (100 nM, 16
h) markedly up-regulated ATF3 in vitro. B) Similarly, in subcutaneous
tumor models of gastric (TMK-1), or pancreatic (L3.6pl) cancer,
treatment with the Hsp90 inhibitor 17-DMAG (3 × 25 mg/kg/week)
up-regulated ATF3 in protein extracts from excised tumors after
14 days.
Figure 2 Identification of signaling pathways for regulating
ATF3. MAPK/Erk (UO), PI-3K/Akt (LY), SAPK (SP), or p38 (SB)
inhibitors were used to identify signaling pathways involved in up-
regulation of ATF3 in HCT116 colon cancer cells. A) Real-time PCR
for ATF3 was performed after 1 hour incubation with indicated
signaling inhibitors. Inhibition of SAPK (SP) significantly up-regulated
ATF3 mRNA expression (P < 0.05). B) On a protein level, after 20
hours incubation with inhibitors, MAPK/Erk, SAPK and p38 pathways
appeared to be involved in mediating ATF3 up-regulation. Bars:
mean ± SEM.
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not different (data not shown). These in vivo results
were confirmed by using one additional ATF3-shRNA
transfected HCT116 clone (data not shown). Moreover,
tumors from mice in the ATF3-shRNA group showed
higher vascularisation in terms of an increased CD31-
positve vessel area (Figure 4C). We conclude from these
experiments that ATF3 functions as a tumor suppressor
and growth-inhibitory factor in HCT116 colon cancer.
Impact of ATF3 down-regulation on colon cancer
metastasis in vivo
We next tested the effects of inhibited ATF3 expression
on tumor metastasis in vivo in a model of hepatic tumor
growth and in a model of peritoneal carcinomatosis. ATF3
silencing in HCT116 led to a substantial increase in hepa-
tic tumor burden, as compared to Luc-shRNA transfected
controls (Figure 5A, B). Furthermore, animals in the
ATF3-shRNA group developed significantly more hepatic
tumor nodules in liver lobes that had not been injected
with tumor cells (Figure 5C). Similarly, in the peritoneal
carcinomatosis model, animals in the ATF3-shRNA group
developed multiple peritoneal nodules and 2/4 (50%) ani-
mals had detectable ascites (Figure 6A, B). These in vivo
experiments support the hypothesis that ATF3 functions
as a tumor suppressor and anti-metastatic factor in
HCT116 colon cancer.
Expression of ATF3 in human colon cancer specimens
Since studies report conflicting results regarding the role
and expression of ATF3 in colorectal cancers, we deter-
mined ATF3 mRNA expression in human colon cancer
specimens. These results show that ATF3 is consistently
expressed at exceptionally low levels in colon cancer
tissues, as compared to corresponding normal tissues
(Figure 7). We conclude that ATF3 is likely to be down-
regulated in colon cancers, hence supporting the ratio-
nale of therapeutically inducing ATF3 expression in this
cancer entity.
Figure 3 Effect of ATF3 down-regulation in vitro. Human colon
cancer cells (HCT116) were stably transfected with either an ATF3-
shRNA, or Luc-shRNA (control) vector, for elucidating the functional
role of AFT3. A) Western blot analysis showed a constitutive,
hypoxia-inducible (1% O2 or DFX), and Hsp90-inhibitor (17-DMAG)-
mediated ATF3 expression, which was substantially diminished after
transfection with the ATF3-shRNA plasmid. B) Stable transfection
with the ATF3-shRNA plasmid lowered ATF3 mRNA in HCT116 cells
and abrogated the Hsp90 inhibitor-mediated induction of ATF3. C)
Down-regulation of ATF3 significantly increased the pro-migration
properties of HCT116 cells (*P < 0.05). Bars: mean ± SEM.
Figure 4 Impact of ATF3 down-regulation on subcutaneous
tumor growth in vivo. The effects of ATF3 down-regulation on
tumor growth were investigated in a subcutaneous tumor model.
A) ATF3-shRNA-transfected HCT116 cells showed an accelerated in
vivo growth rate, as compared to Luc-shRNA HCT116 cells (*P <
0.01). B) Changes in tumor growth rate were also reflected by final
tumor weights at day 28 (*P < 0.01). C) CD31-staining demonstrated
increased vascularisation in tumors of the ATF3-shRNA-transfected
group, as compared to controls (*P < 0.05). Bars: mean ± SEM.
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Discussion
Our recent observation that Hsp90 inhibition induces
ATF3 in cancer cells and the lack of clarity regarding
the biological effect of this transcription factor in oncol-
ogy pressed our aim to define the role of ATF3 in colon
cancer. We now have confirmed that blocking Hsp90
does indeed induce ATF3 in various cancer derived cell
lines, including colon (HT29, HCT116), gastric (TMK1),
and pancreatic (L3.6pl) cancer derived cells. Further-
more, this study is the first to demonstrate that loss of
ATF3 via shRNA-mediated down-regulation increases
the migration properties of HCT116 colon cancer cells
in vitro and promotes tumor growth and metastasis in
vivo. Hence, results from this study suggest that ATF3
functions as a tumor suppressor and anti-metastatic fac-
tor in HCT116 colon cancer, which is therapeutically
inducible by blocking Hsp90.
Recent publications have demonstrated a dichotomous
role of ATF3. Depending on the cell type and malig-
nancy, ATF3 can mediate either proliferative and
pro-migration properties, or anti-proliferative and pro-
apoptotic effects [26-29]. For instance, Yin and co-work-
ers have demonstrated in in vitro experiments that
ATF3 induces apoptosis in non-malignant mammary
epithelial cells, but reduces apoptosis and enhances
motility in breast cancer cells, suggesting an oncogenic
role of ATF3 in breast cancer [15]. In colon cancer,
Figure 5 Effect of ATF3 down-regulation on hepatic tumor
growth in vivo. A hepatic tumor cell implantation model was used
to determine the effects of ATF3 down-regulation on hepatic tumor
growth and metastasis of HCT116 cells. A) Animals in the ATF3-
shRNA group had a markedly greater hepatic tumor burden, as
determined by measuring the weight of excised tumors (*P < 0.05).
B) The occurrence of hepatic nodules in liver lobes other than the
injected lobe was significantly greater in animals of the ATF3-shRNA
group (*P < 0.05). C) Representative images of hepatic tumor
burden are shown. Bars: mean ± SEM.
Figure 6 Effect of ATF3 down-regulation on peritoneal tumor
growth and dissemination in vivo. Transfected human colon
cancer cells (HCT116) were implanted into the peritoneal cavity. A)
Down-regulation of ATF3 promoted peritoneal carcinomatosis
formation, as determined by counting peritoneal nodules (*P <
0.05). B) Representative images of peritoneal dissemination in the
ATF3-shRNA group.
Figure 7 Expression of ATF3 in human colon cancer .
Corresponding colon cancer and non-tumorous tissues of patients
with surgically resected colon cancer (T3-T4) were analyzed by PCR
for the expression of ATF3. The expression of ATF3mRNA was
markedly reduced in colon cancer specimens. Bars: mean ± SEM.
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down-regulating ATF3 in HT29 colon cancer cells with
antisense oligonucleotides apparently diminished entopic
tumor growth and metastasis in mice [19]. In contrast,
we could show that in HCT116 colon cancer, loss of
ATF3 function does result in a higher pro-migration
capacity in vitro and an accelerated tumor growth with
increased metastasis in vivo. One explanation of this dis-
crepancy might be the different genetic background of
HT29 and HCT116 colon cancer cells. While HCT116
harbors mutant KRAS, HT29 colon cancer cells are wild-
type for KRAS but harbor mutant BRAF. Recent publica-
tions have shown that the KRAS and BRAF mutation
status of colon cancer cells influence the expression rates
of multiple proliferative as well as apoptotic signaling
intermediates (Kikuchi et al, Cancer Res 2009, Oliveira et
al, Oncogene 2003, Seruca et al, 2009), including HIF1a
signaling and the MAPK/Erk and PI3K/Akt pathways
which we identified as interacting with ATF3 (Figure 2).
Furthermore, EGFR-targeting agents are clinically effec-
tive in the treatment of KRAS and BRAF wildtype
tumors, whereas no clinical benefit could be proven for
KRAS or BRAF mutant tumors (Lievre et al, Oncogene
2010). Thus, drug-induced overexpression of ATF3 may
have beneficial effects in only a subset of colon cancer
cells. This important result will be further addressed in
future experiments, where loss of ATF3 function as well
as ATF3-overexpression will be investigated in colon
cancer cells with different genetic background.
In line with our findings in HCT116 colon cancer,
tumor suppressive properties of ATF3 were suggested in
a study by Oh et al., describing that ATF3 acts as tumor-
inhibiting factor in HeLa cervical cancer cells in vitro
[30]. Moreover, Lu and co-workers elegantly demon-
strated that ATF3 is capable of suppressing a Ras-
mediated tumorigenicity of murine fibroblasts (ATF3-/-
versus ATF3+/+ fibroblasts) in an in vitro, as well as in an
in vivo model, hence supporting our hypothesis of a
tumor suppressive role. In conclusion, these discrepan-
cies mirror the complex role of ATF3 which may not
solely depend on the investigated cell line. The biological
function of ATF3 in vivo may rather highly rely on the
microenvironment of a defined tumor entity.
One clinical significance of our findings is that treat-
ment-induced up-regulation of ATF3, as for example via
Hsp90-inhibition or COX-2 inhibition, may be beneficial
in some tumors for reducing growth and metastasis
[8,14]. With respect to COX-2 inhibitors, experimental
studies have nicely demonstrated that ATF3 may med-
iate anti-neoplastic and anti-invasive effects of such
non-steroidal anti-inflammatory drugs [14]. In this
study, overexpression of ATF3 inhibited invasion to a
similar degree as sulindac sulfide treatment and anti-
sense ATF3 increased invasion in vitro. This tumor sup-
pressive effect of ATF3 is also supported by their
findings, where transfection of cancer cells with a full-
length ATF3 vector suppressed tumorigenicity and inva-
siveness in vitro and tumor growth in vivo [14]. How-
ever, this group was not able to validate in an in vivo
setting that loss of ATF3 function is conversely asso-
ciated with increased growth rates and metastasis, hence
our study further expands the knowledge on ATF3 func-
tion beyond these aspects. We observed an enhanced
migration behavior after ATF3 inhibition in vitro and
hypothesized that loss of ATF3 function may also lead
to an increased tumor metastasis in vivo, an aspect that
has not been comprehensively investigated to date. In
subsequent hepatic and peritoneal tumor models, we
were able to demonstrate a significant increase in tumor
burden, cancer dissemination, and tumorigenicity upon
further down-regulating ATF3. Thus, we propose that
ATF3 functions as a tumor suppressor and anti-meta-
static factor in HCT116 colon cancer. Moreover, in a
recent publication, Ameri and colleagues could show
that induction of ATF3 in hypoxic conditions, a com-
mon feature detectable in solid tumors, is independent
of the transcription factor HIF-1a [11]. The factors
HIF-1a and ATF3 are both induced by hypoxia and
other cellular stressors, and both transcription factors
regulate the expression of multiple genes during tumor
progression and metastasis [11].
Importantly, and of high clinical relevance, we could
show in the current and in one preliminary previous
study that ATF3 expression can be induced in cancer
cells by Hsp90 inhibition in vitro and in vivo. Inhibitors
to Hsp90 are currently being investigated in a growing
number of clinical trials http://www.clinicaltrials.gov.
Thus, the present study not only adds an interesting
new aspect to the multiple mechanisms of Hsp90-inhibi-
tion, but also provides reasonable evidence that an
ATF3-induction by Hsp90 inhibition could be favorable
for therapy of advanced colon cancer.
Conclusion
In conclusion, the present study shows that down-regu-
lation of ATF3 enhances both invasive properties and
tumor metastasis of HCT116 colon cancer cells in vivo.
Our data suggest that induction of ATF3 may be valu-
able for improving therapy of colorectal cancer patients
in terms of preventing hepatic and peritoneal metasta-
sis. Furthermore, our study provides evidence that such
ATF3-induction can be achieved by Hsp90-inhibition,
which is particularly interesting since Hsp90-inhibitors
are promising new agents for targeted therapy of
advanced colorectal cancer and other malignancies [2].
Abbreviation list
17-DMAG: 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin; ATF3:
activating transcription factor-3; CREB: cyclic AMP response element binding
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protein; DMEM: Dulbecco’s modified Eagle Medium; GLUT-1: glucose-
transporter-1; HIF-1a: hypoxia inducible factor-1alpha; HSF1: heat shock
transcription factor 1; HSP70: heat shock protein 70; HSP90: heat shock
protein 90; MAPK: mitogen-activated protein kinase; MTT-ASSAY: (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tetrazole assay; PBS:
phosphate buffered saline; PI-3K: phosphoinositide-3 kinase; SAPK: stress-
activated protein kinase.
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